Nevirapine Viatris

Nevirapine, the active ingredient in Nevirapine Viatris, is a non-nucleoside reverse transcriptase inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of HIV-1 infection in adults and children, and may be used as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Nevirapine is used in antiretroviral regimens that target HIV-1 replication.

- HIV-1 infection: reduces viral load and helps restore immune function when combined with other antiretrovirals. - Prevention of mother-to-child transmission of HIV-1: included in maternal regimens to lower transmission risk during pregnancy and delivery. - Treatment-experienced HIV-1 patients: employed as part of salvage therapy when resistance to other agents has developed.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions, often pruritic. - Nausea: transient gastrointestinal discomfort. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, potentially leading to jaundice or hepatic failure. - Stevens-Johnson syndrome: severe mucocutaneous reaction requiring immediate medical attention. - Severe hypersensitivity reactions: including anaphylaxis or drug reaction with eosinophilia and systemic symptoms (DRESS).

When prescribing Nevirapine, clinicians should observe several safety precautions to minimize risk.

- Baseline liver assessment: obtain hepatic function tests before initiation and monitor regularly. - Rash monitoring: discontinue immediately if a severe or widespread rash develops. - Pregnancy considerations: avoid use during the first trimester due to increased risk of hepatotoxicity. - Drug-interaction review: assess concomitant medications that affect CYP3A4 metabolism. - Patient counseling: advise patients to report any signs of liver dysfunction or skin reactions promptly. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Nevirapine interacts with several medicines through hepatic enzyme modulation and additive toxicities.

Major Interactions (Avoid): - Rifampicin: strong CYP3A4 inducer that markedly reduces nevirapine plasma levels, compromising efficacy. - Protease inhibitors boosted with ritonavir: potent CYP3A4 inhibitors that increase nevirapine concentrations, raising toxicity risk. - Co-administration with other NNRTIs: may lead to overlapping toxicity and unpredictable pharmacokinetics.

Moderate Interactions (Monitor Closely): - Warfarin: nevirapine can alter anticoagulant effect; monitor INR closely. - Methadone: may reduce methadone levels, requiring dose adjustment. - Hormonal contraceptives: nevirapine can decrease steroid levels; advise additional contraceptive measures.